







Supplemental table 1. Disease progression and outcome in retinopathy positive and retinopathy negative children, compared by HIV status.  
Sequelae refers to neurological sequelae including focal muscle weakness, visual or hearing defects, gross cognitive deficit or epilepsy.  
 
 
Variable RETINOPATHY POSITIVE RETINOPATHY NEGATIVE 
 HIV-uninfected (N=751) HIV infected (N=126)  HIV-uninfected (N=369) HIV-infected (N=59)  
 N Value N Value p N Value N Value p 
Parasite Clearance Time, hours (IQR) 596 42 (30-54) 97 42 (28-54) 0.63 369 36 (24 - 48) 59 42 (24 - 54) 0.37 
Fever Clearance Time, hours (IQR) 591 32 (20-54) 90 37 (20-74) 0.069 369 24 (6 - 38) 59 32 (6 - 58) 0.10 
Coma Resolution Time, hours (IQR) 563 34 (18-56) 90 42 (22-70) 0.0085 369 18 (10 - 38) 59 16 (6 - 32) 0.32 
Fatal-outcome, number (%) 750 140 (18.7%) 126 30 (23.8%) 0.27 367 36 (9.81%) 58 8 (13.8%) 0.86 
Survived with sequelae, number (%) 750 64 (8.53%) 126 9 (7.14%) 0.51 367 38 (10.4%) 58 6 (10.3%) 0.56 
 Supplementary table 2:  Comparison between year categories: 1996-2000; 2001-2005; 2006-2011 
Year category 1996-2000; 2001-2005 2006-2011 
N ret positive 
CM 
310 143 424 
HIV 
prevalence  
36/310 (11.61%) 34/143 (23.78%) 56/424 (13.21%) 
 HIV neg HIV pos  P value HIV neg HIV pos  P value HIV neg HIV pos  P value 













Age (months) 32 (21-50) 45.5 (19-43) 0.0039 29 (19-43) 50.5 (34-75) 0.0025 37 (28-54.5) 
 


























































0.5712 110 (100- 
120) 













Neck stiffness 16/265 
(6.04%) 
3/36 (8.33%) 0.484 4/107 
(3.74%) 
1/32 (3.03%) 1.000 10/357 
(2.72%) 
4/56 (7.14%) 0.100 
Jaundice 
noted  
N/A N/A N/A N/A N/A N/A 26/325 (8%) 4/46 (8.7%) 0.777 
Laboratory 
results 
         
Admission 
parasitaemia 





































































































         
Length of 
stay (days) 



















7/34 (20.59%) 0.505 61/367 
(16.62%) 





1/36 (2.78%) 0.383 10/109 
(9.17%) 
4/34 (11.76%) 0.658 28/367 
(7.63%) 
4/56 (7.14%) 0.308 
 
Supplemental table 3:  Univariate logistic analysis for lactate, gender, age and HIV status 
Variable OR 95% Confidence interval  p-value 
Age      0.998 0.991    1.005 0.52 
Sex/Gender 1.114 0.0794    1.562 0.53 
Admission lactate 1.117 1.064  - 1.174 <0.0001 
HIV status 1.303 0.828 -  2.050 0.25 
 
Supplemental table 4: Multivariate analysis of mortality outcome with age, lactate levels, HIV 
status and sex as covariates 
Variable OR 95% CI p-value 
Age 1.004 0.999-1.009 0.092      
Sex  1.131    0.776-1.652 0.52  
Lactate 1.100 1.043-1.160 <.001 
HIV status 1.222    0.836-2.937 0.57   
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